Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study

• Autoři: LASSUS Johan; GAYAT Etienne; MUELLER Christian; PEACOCK Frank W.; ŠPINAR Jindřich; HARJOLA Veli-Pekka; PASCUAL-FIGAL Domingo; LARIBI Said; LOGEART Damien; NOUIRA Semir; METRA Marco; KIMMENADE Roland von; PATHAK Atul; MUELLER Thomas; SOMMA Salvatore di; SATO Naoki; POTOCKI Michael; PAŘENICA Jiří; COLLET Corinne; COHEN-SOLAL Alain; JANUZZI James L. Jr.; MEBAZAA Alexandre
• Rok publikování: 2013
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: International Journal of Cardiology
• Fakulta / Pracoviště MU: Lékařská fakulta
• Doi: http://dx.doi.org/10.1016/j.ijcard.2013.01.228
• Obor: Kardiovaskulární nemoci včetně kardiochirurgie
• Klíčová slova: ADHF; Mortality; Risk prediction; Biomarkers; Reclassification
• Popis: Aim: This study aims to evaluate the incremental value of plasma biomarkers to traditional clinical variables for risk stratification of 30-day and one-year mortality in acutely decompensated heart failure (ADHF). Methods and results: Through an international collaborative network, individual patient data on 5306 patients hospitalized for ADHF were collected. The all-cause mortality rate was 11.7% at 30 days and 32.9% at one year. The clinical prediction model (age, gender, blood pressure on admission, estimated glomerular filtration rate <60mL/min/1.73 m(2), sodium and hemoglobin levels, and heart rate) had a c-statistic of 0.74 for 30-day mortality and 0.73 for one-year mortality. Several biomarkers measured at presentation improved risk stratification when added to the clinical model. At 30 days, the net reclassification improvement (NRI) was 28.7% for mid-regional adrenomedullin (MR-proADM; p<0.001) and 25.5% for soluble (s) ST2 (p<.001). At one year, sST2 (NRI 10.3%), MR-proADM (NRI 9.1%), amino-terminal pro-B-type natriuretic peptide (NT-proBNP; NRI 9.1%), mid-regional proatrial natriuretic peptide (MR-proANP; NRI 7.4%), B-type natriuretic peptide (NRI 5.5%) and C-reactive protein (CRP; NRI 5.3%) reclassified patients with ADHF (p<0.05 for all). CRP also markedly improved risk stratification of patients with ADHF as a dual biomarker combination with MR-proADM (NRI 36.8% [p<0.001] for death at 30 days) or with sST2 (NRI 20.3%; [p<0.001] for one-year mortality). Conclusion: In this study, biomarkers provided incremental value for risk stratification of ADHF patients. Biomarkers such as sST2, MR-proADM, natriuretic peptides and CRP, reflecting different pathophysiologic pathways, add prognostic value to clinical risk factors for predicting both short-term and one-year mortality in ADHF.